Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 1744 CL versus formoterol and placebo in COPD
2008-001934-28Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of olodaterol, formoterol and Placebo-COD Research Private Ltd in chronic obstructive pulmonary disease (COPD) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoints: FEV1 response and Mahler Transitional Dyspnea Index focal score. Started Oct 2008; status: completed.
02
Drugs
olodaterolformoterolPlacebo-COD Research Private Ltd
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2008-001934-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001934-28.